Calciphylaxis - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Calciphylaxis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Calciphylaxis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Calciphylaxis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Calciphylaxis - Disease Understanding and Treatment Algorithm Calciphylaxis, a rare and lethal syndrome of vascular calcification, is characterized by occlusion of micro vessels in the subcutaneous adipose tissue and dermis that results in painful, ischemic skin lesions. Patients with end-stage renal disease (ESRD) are typically affected by this disorder. ESRD includes a population with a high prevalence of extra skeletal calcifications. A clear majority of such calcifications do not represent calciphylaxis, which cannot be placed on a simple continuum of vascular calcification. Another group of population which is mainly affected by the Calciphylaxis involve patients with earlier stages of chronic kidney disease, acute kidney injury, or prior receipt of a kidney transplant and in rare cases, it occurs in patients with normal kidney function. Owing to these conditions, calciphylaxis is widely used interchangeably with Calcific Uremic Arteriolopathy (CUA), which is another name for this entity. The DelveInsight Calciphylaxis market report gives the thorough understanding of the Calciphylaxis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Calciphylaxis in the US, Europe, and Japan. Calciphylaxis Epidemiology The Calciphylaxis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population, Gender – Specific Incident Population and Age – Specific Incident Population] scenario of Calciphylaxis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. According to DelveInsight’s estimates, total incident population in the 7MM was approximately 2,800 in 2016 and is expected to grow at a CAGR of 0.67% for the study period [2016-2027]. In terms of Sex-specific epidemiology of the disease, most of the patients who have been diagnosed with calciphylaxis are female. Among 7MM, US has highest incident population of Calciphylaxis, Germany had the highest incident population of calciphylaxis, followed by the United Kingdom among EU-5 countries. Based on the DelveInsight analysis, the age-specific data revealed that the highest number of people affected with Calciphylaxis were found in the age-group of 65-84 years, while people who belonged to the age group 1-17 years are the least affected. Calciphylaxis Drug Chapters This segment of the Calciphylaxis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Due to the lack of approved therapeutic regimens for calciphylaxis, management involves a multidisciplinary approach, consisting of primary prevention, wound care and infection prophylaxis, controlling disease progression, and treatment of the systemic disease. The current therapeutic landscape of Calciphylaxis can be broadly divided into two categories: Conventional Treatment and Combination Treatment (multi-target). The mainstays of therapy include the removal of potential trigger agents, wound care, and antibiotics supplemented with intensified hemodialysis, use of chelating agents (sodium thiosulfate, and deferoxamine), and treatment of hyperparathyroidism and hyperphosphatemia with cinacalcet and non-phosphate calcium binders, respectively. Calciphylaxis Market Outlook The Calciphylaxis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Therapeutic market of Calciphylaxis in the seven major markets is expected to reach USD XX million by 2027 at a compound Annual Growth Rate (CAGR) of 4.13% for the forecast period 2016-2027. The United States had the highest market size of Calciphylaxis in 2016, which accounts for approximately 85% of the total market. On the contrary, Spain accounted for the least market share (1.20%) among the 7MM countries. Among the different class of off label therapies such as Sodium thiosulfate, Bisphosphonates, Cinacalcet, Non-calcium chelators, Vitamin K and others, Sodium thiosulfate is the most prescribed therapies, that led to highest market size among other therapies. Calciphylaxis Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Expected launch of Sodium thiosulfate for the treatment of Calciphylaxis (Hope Pharmaceuticals), and SNF472 (Sanifit), during the forecast period (2018-2027) is also expected to create a positive impact on the Calciphylaxis market. Calciphylaxis Report Insights Patient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies Calciphylaxis Report Key Strengths 10 Years Forecast 7MM Coverage Epidemiology Segmentation Key Cross Competition Market Size by Therapies Drugs Uptake Calciphylaxis Report Assessment Pipeline Product Profiles Key Products and Key Players Market Drivers and Barriers Key Benefits This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Calciphylaxis market Organize sales and marketing efforts by identifying the best opportunities for Calciphylaxis market To understand the future market competition in the Calciphylaxis market.
DelveInsight’s ‘Calciphylaxis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Calciphylaxis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Calciphylaxis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Calciphylaxis - Disease Understanding and Treatment Algorithm Calciphylaxis, a rare and lethal syndrome of vascular calcification, is characterized by occlusion of micro vessels in the subcutaneous adipose tissue and dermis that results in painful, ischemic skin lesions. Patients with end-stage renal disease (ESRD) are typically affected by this disorder. ESRD includes a population with a high prevalence of extra skeletal calcifications. A clear majority of such calcifications do not represent calciphylaxis, which cannot be placed on a simple continuum of vascular calcification. Another group of population which is mainly affected by the Calciphylaxis involve patients with earlier stages of chronic kidney disease, acute kidney injury, or prior receipt of a kidney transplant and in rare cases, it occurs in patients with normal kidney function. Owing to these conditions, calciphylaxis is widely used interchangeably with Calcific Uremic Arteriolopathy (CUA), which is another name for this entity. The DelveInsight Calciphylaxis market report gives the thorough understanding of the Calciphylaxis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Calciphylaxis in the US, Europe, and Japan. Calciphylaxis Epidemiology The Calciphylaxis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population, Gender – Specific Incident Population and Age – Specific Incident Population] scenario of Calciphylaxis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. According to DelveInsight’s estimates, total incident population in the 7MM was approximately 2,800 in 2016 and is expected to grow at a CAGR of 0.67% for the study period [2016-2027]. In terms of Sex-specific epidemiology of the disease, most of the patients who have been diagnosed with calciphylaxis are female. Among 7MM, US has highest incident population of Calciphylaxis, Germany had the highest incident population of calciphylaxis, followed by the United Kingdom among EU-5 countries. Based on the DelveInsight analysis, the age-specific data revealed that the highest number of people affected with Calciphylaxis were found in the age-group of 65-84 years, while people who belonged to the age group 1-17 years are the least affected. Calciphylaxis Drug Chapters This segment of the Calciphylaxis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Due to the lack of approved therapeutic regimens for calciphylaxis, management involves a multidisciplinary approach, consisting of primary prevention, wound care and infection prophylaxis, controlling disease progression, and treatment of the systemic disease. The current therapeutic landscape of Calciphylaxis can be broadly divided into two categories: Conventional Treatment and Combination Treatment (multi-target). The mainstays of therapy include the removal of potential trigger agents, wound care, and antibiotics supplemented with intensified hemodialysis, use of chelating agents (sodium thiosulfate, and deferoxamine), and treatment of hyperparathyroidism and hyperphosphatemia with cinacalcet and non-phosphate calcium binders, respectively. Calciphylaxis Market Outlook The Calciphylaxis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Therapeutic market of Calciphylaxis in the seven major markets is expected to reach USD XX million by 2027 at a compound Annual Growth Rate (CAGR) of 4.13% for the forecast period 2016-2027. The United States had the highest market size of Calciphylaxis in 2016, which accounts for approximately 85% of the total market. On the contrary, Spain accounted for the least market share (1.20%) among the 7MM countries. Among the different class of off label therapies such as Sodium thiosulfate, Bisphosphonates, Cinacalcet, Non-calcium chelators, Vitamin K and others, Sodium thiosulfate is the most prescribed therapies, that led to highest market size among other therapies. Calciphylaxis Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Expected launch of Sodium thiosulfate for the treatment of Calciphylaxis (Hope Pharmaceuticals), and SNF472 (Sanifit), during the forecast period (2018-2027) is also expected to create a positive impact on the Calciphylaxis market. Calciphylaxis Report Insights Patient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies Calciphylaxis Report Key Strengths 10 Years Forecast 7MM Coverage Epidemiology Segmentation Key Cross Competition Market Size by Therapies Drugs Uptake Calciphylaxis Report Assessment Pipeline Product Profiles Key Products and Key Players Market Drivers and Barriers Key Benefits This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Calciphylaxis market Organize sales and marketing efforts by identifying the best opportunities for Calciphylaxis market To understand the future market competition in the Calciphylaxis market.
1. KEY INSIGHTS
2. CALCIPHYLAXIS: MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Calciphylaxis in 2016
2.2. Total Market Share (%) Distribution of Calciphylaxis in 2027
2.3. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2016
2.4. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2027
3. CALCIPHYLAXIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Clinical Manifestations
3.3. Pathophysiology of Calciphylaxis
3.3.1. Reactive Oxygen Species (ROS) in Pathogenesis of CUA/Calciphylaxis
3.4. Clinical Classification
3.5. Risk Factors of Calciphylaxis
3.5.1. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) Axis Abnormalities
3.5.2. Demographic Factors
3.5.3. Co-morbid Conditions
3.6. Diagnosis of Calciphylaxis
3.6.1. Differential Diagnosis
3.6.2. Biopsy
3.6.3. Radiological Tests and Biomarkers
3.6.4. Laboratory Evaluation
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
5. TOTAL INCIDENT POPULATION OF CALCIPHYLAXIS IN 7MM
6. COUNTRY WISE-EPIDEMIOLOGY OF CALCIPHYLAXIS
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of Calciphylaxis in the United States
6.1.3. Gender – Specific Incident Population of Calciphylaxis in the United States
6.1.4. Age – Specific Incident Population of Calciphylaxis in the United States
6.2. EU5 countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Assumptions and rationale
6.3.2. Total Incident Population of Calciphylaxis in Germany
6.3.3. Gender – Specific Incident Population of Calciphylaxis in Germany
6.3.4. Age – Specific Incident Population of Calciphylaxis in Germany
6.4. France
6.4.1. Assumptions and rationale
6.4.2. Total Incident Population of Calciphylaxis in France
6.4.3. Gender – Specific Incident Population of Calciphylaxis in France
6.4.4. Age – Specific Incident Population of Calciphylaxis in France
6.5. Italy
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of Calciphylaxis in Italy
6.5.3. Gender – Specific Incident Population of Calciphylaxis in Italy
6.5.4. Age – Specific Incident Population of Calciphylaxis in Italy
6.6. Spain
6.6.1. Assumptions and Rationale
6.6.2. Total Incident Population of Calciphylaxis in Spain
6.6.3. Gender – Specific Incident Population of Calciphylaxis in Spain
6.6.4. Age – Specific Incident Population of Calciphylaxis in Spain
6.7. United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Incident Population of Calciphylaxis in the United Kingdom
6.7.3. Gender – Specific Incident Population of Calciphylaxis in the United Kingdom
6.7.4. Age – Specific Incident Population of Calciphylaxis in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Incident Population of Calciphylaxis in the Japan
6.8.3. Gender – Specific Incident Population of Calciphylaxis in the Japan
6.8.4. Age – Specific Incident Population of Calciphylaxis in Japan
7. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8. UNMET NEEDS
9. EMERGING THERAPIES
9.1. Key Cross Competition
9.2. Sodium Thiosulfate: Hope Pharmaceuticals
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. SNF472: Sanifit
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
10. DISCONTINUED PRODUCT
10.1. Sodium thiosulfate: Luitpold Pharmaceuticals
10.1.1. Product Description
10.1.2. Clinical Development
10.1.3. Product Profile
11. CALCIPHYLAXIS: 7MM MARKET ANALYSIS
11.1. Key Findings
11.2. Market Size of Calciphylaxis in 7MM countries
11.3. Market Size of Calciphylaxis by therapies in 7MM
12. UNITED STATES: MARKET OUTLOOK
12.1. United States Market Size
12.1.1. Total Market size of Calciphylaxis
12.1.2. Market Size of Calciphylaxis by therapies in the US
13. EU-5 COUNTRIES: MARKET OUTLOOK
13.1. Germany Market Size
13.1.1. Total Market size of Calciphylaxis
13.1.2. Market Size of Calciphylaxis by therapies in Germany
13.2. France Market Size
13.2.1. Total Market size of Calciphylaxis
13.2.2. Market Size of Calciphylaxis by therapies in France
13.3. Italy Market Size
13.3.1. Total Market size of Calciphylaxis
13.3.2. Market Size of Calciphylaxis by therapies in Italy
13.4. Spain Market Size
13.4.1. Total Market size of Calciphylaxis
13.4.2. Market Size of Calciphylaxis by therapies in Spain
13.5. United Kingdom Market Size
13.5.1. Total Market size of Calciphylaxis
13.5.2. Market Size of Calciphylaxis by therapies in the UK
14. JAPAN MARKET OUTLOOK
14.1. Japan Market Size
14.1.1. Total Market size of Calciphylaxis
14.1.2. Market Size of Calciphylaxis by therapies in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. CALCIPHYLAXIS: MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of Calciphylaxis in 2016
2.2. Total Market Share (%) Distribution of Calciphylaxis in 2027
2.3. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2016
2.4. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2027
3. CALCIPHYLAXIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Clinical Manifestations
3.3. Pathophysiology of Calciphylaxis
3.3.1. Reactive Oxygen Species (ROS) in Pathogenesis of CUA/Calciphylaxis
3.4. Clinical Classification
3.5. Risk Factors of Calciphylaxis
3.5.1. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) Axis Abnormalities
3.5.2. Demographic Factors
3.5.3. Co-morbid Conditions
3.6. Diagnosis of Calciphylaxis
3.6.1. Differential Diagnosis
3.6.2. Biopsy
3.6.3. Radiological Tests and Biomarkers
3.6.4. Laboratory Evaluation
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
5. TOTAL INCIDENT POPULATION OF CALCIPHYLAXIS IN 7MM
6. COUNTRY WISE-EPIDEMIOLOGY OF CALCIPHYLAXIS
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of Calciphylaxis in the United States
6.1.3. Gender – Specific Incident Population of Calciphylaxis in the United States
6.1.4. Age – Specific Incident Population of Calciphylaxis in the United States
6.2. EU5 countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Assumptions and rationale
6.3.2. Total Incident Population of Calciphylaxis in Germany
6.3.3. Gender – Specific Incident Population of Calciphylaxis in Germany
6.3.4. Age – Specific Incident Population of Calciphylaxis in Germany
6.4. France
6.4.1. Assumptions and rationale
6.4.2. Total Incident Population of Calciphylaxis in France
6.4.3. Gender – Specific Incident Population of Calciphylaxis in France
6.4.4. Age – Specific Incident Population of Calciphylaxis in France
6.5. Italy
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of Calciphylaxis in Italy
6.5.3. Gender – Specific Incident Population of Calciphylaxis in Italy
6.5.4. Age – Specific Incident Population of Calciphylaxis in Italy
6.6. Spain
6.6.1. Assumptions and Rationale
6.6.2. Total Incident Population of Calciphylaxis in Spain
6.6.3. Gender – Specific Incident Population of Calciphylaxis in Spain
6.6.4. Age – Specific Incident Population of Calciphylaxis in Spain
6.7. United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Incident Population of Calciphylaxis in the United Kingdom
6.7.3. Gender – Specific Incident Population of Calciphylaxis in the United Kingdom
6.7.4. Age – Specific Incident Population of Calciphylaxis in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Incident Population of Calciphylaxis in the Japan
6.8.3. Gender – Specific Incident Population of Calciphylaxis in the Japan
6.8.4. Age – Specific Incident Population of Calciphylaxis in Japan
7. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8. UNMET NEEDS
9. EMERGING THERAPIES
9.1. Key Cross Competition
9.2. Sodium Thiosulfate: Hope Pharmaceuticals
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. SNF472: Sanifit
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
10. DISCONTINUED PRODUCT
10.1. Sodium thiosulfate: Luitpold Pharmaceuticals
10.1.1. Product Description
10.1.2. Clinical Development
10.1.3. Product Profile
11. CALCIPHYLAXIS: 7MM MARKET ANALYSIS
11.1. Key Findings
11.2. Market Size of Calciphylaxis in 7MM countries
11.3. Market Size of Calciphylaxis by therapies in 7MM
12. UNITED STATES: MARKET OUTLOOK
12.1. United States Market Size
12.1.1. Total Market size of Calciphylaxis
12.1.2. Market Size of Calciphylaxis by therapies in the US
13. EU-5 COUNTRIES: MARKET OUTLOOK
13.1. Germany Market Size
13.1.1. Total Market size of Calciphylaxis
13.1.2. Market Size of Calciphylaxis by therapies in Germany
13.2. France Market Size
13.2.1. Total Market size of Calciphylaxis
13.2.2. Market Size of Calciphylaxis by therapies in France
13.3. Italy Market Size
13.3.1. Total Market size of Calciphylaxis
13.3.2. Market Size of Calciphylaxis by therapies in Italy
13.4. Spain Market Size
13.4.1. Total Market size of Calciphylaxis
13.4.2. Market Size of Calciphylaxis by therapies in Spain
13.5. United Kingdom Market Size
13.5.1. Total Market size of Calciphylaxis
13.5.2. Market Size of Calciphylaxis by therapies in the UK
14. JAPAN MARKET OUTLOOK
14.1. Japan Market Size
14.1.1. Total Market size of Calciphylaxis
14.1.2. Market Size of Calciphylaxis by therapies in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Differential diagnosis for calcific uremic arteriolopathy (calciphylaxis)
Table 2: Laboratory evaluation of patients with calciphylaxis.
Table 3: Total Incident Population of Calciphylaxis in the 7MM (2016-2027)
Table 4: Total Incident Population of Calciphylaxis in the US (2016-2027)
Table 5: Gender Specific Incidence of Calciphylaxis in the US (2016-2027)
Table 6: Age-Specific Incidence of Calciphylaxis in the US (2016-2027)
Table 7: Total Incident Population of Calciphylaxis in Germany (2016-2027)
Table 8: Gender Specific Incidence of Calciphylaxis in Germany (2016-2027)
Table 9: Age-Specific Incidence of Calciphylaxis in the Germany (2016-2027)
Table 10: Total Incident Population of Calciphylaxis in France (2016-2027)
Table 11: Gender Specific Incidence of Calciphylaxis in France (2016-2027)
Table 12: Age-Specific Incidence of Calciphylaxis in France (2016-2027)
Table 13: Total Incident Population of Calciphylaxis in Italy (2016-2027)
Table 14: Gender Specific Incidence of Calciphylaxis in Italy (2016-2027)
Table 15: Age-Specific Incidence of Calciphylaxis in Italy (2016-2027)
Table 16: Total Incident Population of Calciphylaxis in Spain (2016-2027)
Table 17: Gender Specific Incidence of Calciphylaxis in Spain (2016-2027)
Table 18: Age-Specific Incidence of Calciphylaxis in Spain (2016-2027)
Table 19: Total Incident Population of Calciphylaxis in the UK (2016-2027)
Table 20: Gender Specific Incidence of Calciphylaxis in the UK (2016-2027)
Table 21: Age-Specific Incidence of Calciphylaxis in the UK (2016-2027)
Table 22: Total Incident Population of Calciphylaxis in the Japan (2016-2027)
Table 23: Gender Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Table 24: Age-Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Table 25: Summary of treatment approach for uremic calciphylaxis
Table 26: Emerging Drugs Analysis
Table 27: Sodium Thiosulfate (Hope Pharmaceutical), Clinical Trial Description, 2018
Table 28: SNF472 (Sanifit), Clinical Trial Description, 2018
Table 29: Sodium thiosulfate (Luitpold Pharmaceuticals), Clinical Trial Description, 2018
Table 30: Market Size of Calciphylaxis in 7MM in USD Million (2016-2027)
Table 31: Market Size of Calciphylaxis by therapies in the 7MM, in USD Million (2016-2027)
Table 32: The US Market Size of Calciphylaxis in USD Million (2016-2027)
Table 33: Market Size of Calciphylaxis by therapies in the US in USD Million (2016-2027)
Table 34: Germany Market Size of Calciphylaxis in USD Million (2016-2027)
Table 35: Market Size of Calciphylaxis by therapies in Germany in USD Million (2016-2027)
Table 36: France Market Size of Calciphylaxis in USD Million (2016-2027)
Table 37: Market Size of Calciphylaxis by therapies in France in USD Million (2016-2027)
Table 38: Italy Market Size of Calciphylaxis in USD Million (2016-2027)
Table 39: Market Size of Calciphylaxis by therapies in Italy in USD Million (2016-2027)
Table 40: Spain Market Size of Calciphylaxis in USD Million (2016-2027)
Table 41: Market Size of Calciphylaxis by therapies in Spain in USD Million (2016-2027)
Table 42: The UK Market Size of Calciphylaxis in USD Million (2016-2027)
Table 43: Market Size of Calciphylaxis by therapies in the UK in USD Million (2016-2027)
Table 44: Japan Market Size of Calciphylaxis in USD Million (2016-2027)
Table 45: Market Size of Calciphylaxis by therapies in Japan in USD Million (2016-2027)
Table 1: Differential diagnosis for calcific uremic arteriolopathy (calciphylaxis)
Table 2: Laboratory evaluation of patients with calciphylaxis.
Table 3: Total Incident Population of Calciphylaxis in the 7MM (2016-2027)
Table 4: Total Incident Population of Calciphylaxis in the US (2016-2027)
Table 5: Gender Specific Incidence of Calciphylaxis in the US (2016-2027)
Table 6: Age-Specific Incidence of Calciphylaxis in the US (2016-2027)
Table 7: Total Incident Population of Calciphylaxis in Germany (2016-2027)
Table 8: Gender Specific Incidence of Calciphylaxis in Germany (2016-2027)
Table 9: Age-Specific Incidence of Calciphylaxis in the Germany (2016-2027)
Table 10: Total Incident Population of Calciphylaxis in France (2016-2027)
Table 11: Gender Specific Incidence of Calciphylaxis in France (2016-2027)
Table 12: Age-Specific Incidence of Calciphylaxis in France (2016-2027)
Table 13: Total Incident Population of Calciphylaxis in Italy (2016-2027)
Table 14: Gender Specific Incidence of Calciphylaxis in Italy (2016-2027)
Table 15: Age-Specific Incidence of Calciphylaxis in Italy (2016-2027)
Table 16: Total Incident Population of Calciphylaxis in Spain (2016-2027)
Table 17: Gender Specific Incidence of Calciphylaxis in Spain (2016-2027)
Table 18: Age-Specific Incidence of Calciphylaxis in Spain (2016-2027)
Table 19: Total Incident Population of Calciphylaxis in the UK (2016-2027)
Table 20: Gender Specific Incidence of Calciphylaxis in the UK (2016-2027)
Table 21: Age-Specific Incidence of Calciphylaxis in the UK (2016-2027)
Table 22: Total Incident Population of Calciphylaxis in the Japan (2016-2027)
Table 23: Gender Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Table 24: Age-Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Table 25: Summary of treatment approach for uremic calciphylaxis
Table 26: Emerging Drugs Analysis
Table 27: Sodium Thiosulfate (Hope Pharmaceutical), Clinical Trial Description, 2018
Table 28: SNF472 (Sanifit), Clinical Trial Description, 2018
Table 29: Sodium thiosulfate (Luitpold Pharmaceuticals), Clinical Trial Description, 2018
Table 30: Market Size of Calciphylaxis in 7MM in USD Million (2016-2027)
Table 31: Market Size of Calciphylaxis by therapies in the 7MM, in USD Million (2016-2027)
Table 32: The US Market Size of Calciphylaxis in USD Million (2016-2027)
Table 33: Market Size of Calciphylaxis by therapies in the US in USD Million (2016-2027)
Table 34: Germany Market Size of Calciphylaxis in USD Million (2016-2027)
Table 35: Market Size of Calciphylaxis by therapies in Germany in USD Million (2016-2027)
Table 36: France Market Size of Calciphylaxis in USD Million (2016-2027)
Table 37: Market Size of Calciphylaxis by therapies in France in USD Million (2016-2027)
Table 38: Italy Market Size of Calciphylaxis in USD Million (2016-2027)
Table 39: Market Size of Calciphylaxis by therapies in Italy in USD Million (2016-2027)
Table 40: Spain Market Size of Calciphylaxis in USD Million (2016-2027)
Table 41: Market Size of Calciphylaxis by therapies in Spain in USD Million (2016-2027)
Table 42: The UK Market Size of Calciphylaxis in USD Million (2016-2027)
Table 43: Market Size of Calciphylaxis by therapies in the UK in USD Million (2016-2027)
Table 44: Japan Market Size of Calciphylaxis in USD Million (2016-2027)
Table 45: Market Size of Calciphylaxis by therapies in Japan in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Professor Selye's experimental calciphylaxis model
Figure 2: Clinical Manifestations, Radiographic Features, and Histologic Characteristics of Calciphylaxis.
Figure 3: Arteriolar remodeling and vascular calcification in calcific uremic arteriolopathy (CUA)/calciphylaxis.
Figure 4: Early skin changes and histologic findings in calcific uremic arteriolopathy/calciphylaxis.
Figure 5: Potential mechanisms involving uremic toxins and reactive oxygen species (ROS) in vascular calcification.
Figure 6: Uncoupling of the eNOS enzyme results in the endothelium becoming a net producer of superoxide.
Figure 7: Classification of Calciphylaxis
Figure 8: Total Incident Population of Calciphylaxis in the 7MM (2016-2027)
Figure 9: Total Incident Population of Calciphylaxis in the US (2016-2027)
Figure 10: Gender Specific Incidence of Calciphylaxis in the US (2016-2027)
Figure 11: Age-Specific Incidence of Calciphylaxis in the US (2016-2027)
Figure 12: Total Incident Population of Calciphylaxis in Germany (2016-2027)
Figure 13: Gender Specific Incidence of Calciphylaxis in Germany (2016-2027)
Figure 14: Age-Specific Incidence of Calciphylaxis in Germany (2016-2027)
Figure 15: Total Incident Population of Calciphylaxis in France (2016-2027)
Figure 16: Gender Specific Incidence of Calciphylaxis in France (2016-2027)
Figure 17: Age-Specific Incidence of Calciphylaxis in France (2016-2027)
Figure 18: Total Incident Population of Calciphylaxis in Italy (2016-2027)
Figure 19: Gender Specific Incidence of Calciphylaxis in Italy (2016-2027)
Figure 20: Age-Specific Incidence of Calciphylaxis in Italy (2016-2027)
Figure 21: Total Incident Population of Calciphylaxis in Spain (2016-2027)
Figure 22: Gender Specific Incidence of Calciphylaxis in Spain (2016-2027)
Figure 23: Age-Specific Incidence of Calciphylaxis in Spain (2016-2027)
Figure 24: Total Incident Population of Calciphylaxis in the UK (2016-2027)
Figure 25: Gender Specific Incidence of Calciphylaxis in the UK (2016-2027)
Figure 26: Age-Specific Incidence of Calciphylaxis in the UK (2016-2027)
Figure 27: Total Incident Population of Calciphylaxis in the Japan (2016-2027)
Figure 28: Gender Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Figure 29: Age-Specific Incidence of Calciphylaxis in Japan (2016-2027)
Figure 30: An Interdisciplinary Approach to the Management of Calciphylaxis
Figure 31: Unmet Needs of Calciphylaxis
Figure 32: Market Size of Calciphylaxis in the 7MM in USD Million (2016-2027)
Figure 33: Market Size of Calciphylaxis by therapies in 7MM in USD Million (2016-2027)
Figure 34: Market Size of Calciphylaxis in the US, USD Millions (2016-2027)
Figure 35: Market Size of Calciphylaxis by therapies in US in USD Million (2016-2027)
Figure 36: Market Size of Calciphylaxis in Germany, USD Millions (2016-2027)
Figure 37: Market Size of Calciphylaxis by therapies in Germany in USD Million (2016-2027)
Figure 38: Market Size of Calciphylaxis in France, USD Millions (2016-2027)
Figure 39: Market Size of Calciphylaxis by therapies in France in USD Million (2016-2027)
Figure 40: Market Size of Calciphylaxis in Italy, USD Millions (2016-2027)
Figure 41: Market Size of Calciphylaxis by therapies in Italy in USD Million (2016-2027)
Figure 42: Market Size of Calciphylaxis in Spain, USD Millions (2016-2027)
Figure 43: Market Size of Calciphylaxis by therapies in Spain in USD Million (2016-2027)
Figure 44: Market Size of Calciphylaxis in the UK, USD Millions (2016-2027)
Figure 45: Market Size of Calciphylaxis by therapies in the UK in USD Million (2016-2027)
Figure 46: Market Size of Calciphylaxis in the Japan, USD Millions (2016-2027)
Figure 47: Market Size of Calciphylaxis by therapies in Japan in USD Million (2016-2027)
Figure 48: Market Drivers
Figure 49: Market Barriers
Figure 1: Professor Selye's experimental calciphylaxis model
Figure 2: Clinical Manifestations, Radiographic Features, and Histologic Characteristics of Calciphylaxis.
Figure 3: Arteriolar remodeling and vascular calcification in calcific uremic arteriolopathy (CUA)/calciphylaxis.
Figure 4: Early skin changes and histologic findings in calcific uremic arteriolopathy/calciphylaxis.
Figure 5: Potential mechanisms involving uremic toxins and reactive oxygen species (ROS) in vascular calcification.
Figure 6: Uncoupling of the eNOS enzyme results in the endothelium becoming a net producer of superoxide.
Figure 7: Classification of Calciphylaxis
Figure 8: Total Incident Population of Calciphylaxis in the 7MM (2016-2027)
Figure 9: Total Incident Population of Calciphylaxis in the US (2016-2027)
Figure 10: Gender Specific Incidence of Calciphylaxis in the US (2016-2027)
Figure 11: Age-Specific Incidence of Calciphylaxis in the US (2016-2027)
Figure 12: Total Incident Population of Calciphylaxis in Germany (2016-2027)
Figure 13: Gender Specific Incidence of Calciphylaxis in Germany (2016-2027)
Figure 14: Age-Specific Incidence of Calciphylaxis in Germany (2016-2027)
Figure 15: Total Incident Population of Calciphylaxis in France (2016-2027)
Figure 16: Gender Specific Incidence of Calciphylaxis in France (2016-2027)
Figure 17: Age-Specific Incidence of Calciphylaxis in France (2016-2027)
Figure 18: Total Incident Population of Calciphylaxis in Italy (2016-2027)
Figure 19: Gender Specific Incidence of Calciphylaxis in Italy (2016-2027)
Figure 20: Age-Specific Incidence of Calciphylaxis in Italy (2016-2027)
Figure 21: Total Incident Population of Calciphylaxis in Spain (2016-2027)
Figure 22: Gender Specific Incidence of Calciphylaxis in Spain (2016-2027)
Figure 23: Age-Specific Incidence of Calciphylaxis in Spain (2016-2027)
Figure 24: Total Incident Population of Calciphylaxis in the UK (2016-2027)
Figure 25: Gender Specific Incidence of Calciphylaxis in the UK (2016-2027)
Figure 26: Age-Specific Incidence of Calciphylaxis in the UK (2016-2027)
Figure 27: Total Incident Population of Calciphylaxis in the Japan (2016-2027)
Figure 28: Gender Specific Incidence of Calciphylaxis in the Japan (2016-2027)
Figure 29: Age-Specific Incidence of Calciphylaxis in Japan (2016-2027)
Figure 30: An Interdisciplinary Approach to the Management of Calciphylaxis
Figure 31: Unmet Needs of Calciphylaxis
Figure 32: Market Size of Calciphylaxis in the 7MM in USD Million (2016-2027)
Figure 33: Market Size of Calciphylaxis by therapies in 7MM in USD Million (2016-2027)
Figure 34: Market Size of Calciphylaxis in the US, USD Millions (2016-2027)
Figure 35: Market Size of Calciphylaxis by therapies in US in USD Million (2016-2027)
Figure 36: Market Size of Calciphylaxis in Germany, USD Millions (2016-2027)
Figure 37: Market Size of Calciphylaxis by therapies in Germany in USD Million (2016-2027)
Figure 38: Market Size of Calciphylaxis in France, USD Millions (2016-2027)
Figure 39: Market Size of Calciphylaxis by therapies in France in USD Million (2016-2027)
Figure 40: Market Size of Calciphylaxis in Italy, USD Millions (2016-2027)
Figure 41: Market Size of Calciphylaxis by therapies in Italy in USD Million (2016-2027)
Figure 42: Market Size of Calciphylaxis in Spain, USD Millions (2016-2027)
Figure 43: Market Size of Calciphylaxis by therapies in Spain in USD Million (2016-2027)
Figure 44: Market Size of Calciphylaxis in the UK, USD Millions (2016-2027)
Figure 45: Market Size of Calciphylaxis by therapies in the UK in USD Million (2016-2027)
Figure 46: Market Size of Calciphylaxis in the Japan, USD Millions (2016-2027)
Figure 47: Market Size of Calciphylaxis by therapies in Japan in USD Million (2016-2027)
Figure 48: Market Drivers
Figure 49: Market Barriers
